Vol. 5 No. 12 (2025)
Reimbursement Reviews

Lazertinib and Amivantamab (Lazcluze and Rybrevant)

decorative image of the issue cover

Published December 16, 2025

Key Messages

  • Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses lazertinib 80 mg and 240 mg tablets, and amivantamab 350 mg/7 mL (50 mg/mL) single-use vial for IV infusion.
  • Indication: Lazertinib in combination with amivantamab is indicated for the first-line treatment of adult patients with locally advanced (not amenable to curative therapy) or metastatic non–small cell lung cancer with EGFR exon 19 deletions or exon 21 L858R substitution mutations.